Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'- ¹⁸ F-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model.

Autor: Schelhaas S; European Institute for Molecular Imaging, Westfälische Wilhelms-Universität Münster, Münster, Germany., Wachsmuth L; Department of Clinical Radiology, University Hospital of Münster, Münster, Germany., Hermann S; European Institute for Molecular Imaging, Westfälische Wilhelms-Universität Münster, Münster, Germany., Rieder N; Pathology and Tissue Analytics, Roche Pharma Research and Early Development, Roche Innovation Center, Munich, Germany., Heller A; Pathology and Tissue Analytics, Roche Pharma Research and Early Development, Roche Innovation Center, Munich, Germany., Heinzmann K; Comprehensive Cancer Imaging Centre, Imperial College London, London, United Kingdom., Honess DJ; Cancer Research U.K. Cambridge Institute, Cambridge, United Kingdom., Smith DM; Cancer Research U.K. Cambridge Institute, Cambridge, United Kingdom., Fricke IB; European Institute for Molecular Imaging, Westfälische Wilhelms-Universität Münster, Münster, Germany., Just N; Department of Clinical Radiology, University Hospital of Münster, Münster, Germany., Doblas S; Laboratory of Imaging Biomarkers, UMR 1149-CRI, INSERM, Paris Diderot University, Paris, France., Sinkus R; Imaging Sciences and Biomedical Engineering Division, Kings College, London, United Kingdom., Döring C; European Institute for Molecular Imaging, Westfälische Wilhelms-Universität Münster, Münster, Germany., Schäfers KP; European Institute for Molecular Imaging, Westfälische Wilhelms-Universität Münster, Münster, Germany., Griffiths JR; Cancer Research U.K. Cambridge Institute, Cambridge, United Kingdom., Faber C; Department of Clinical Radiology, University Hospital of Münster, Münster, Germany., Schneider R; Merck KGaA, Darmstadt, Germany; and., Aboagye EO; Comprehensive Cancer Imaging Centre, Imperial College London, London, United Kingdom., Jacobs AH; European Institute for Molecular Imaging, Westfälische Wilhelms-Universität Münster, Münster, Germany ahjacobs@uni-muenster.de.; Department of Geriatric Medicine, Johanniter Hospital, Bonn, Germany.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2018 Jul; Vol. 59 (7), pp. 1063-1069. Date of Electronic Publication: 2018 Feb 23.

The therapeutic effect of a novel GAPDH inhibitor in mouse model of breast cancer and efficacy monitoring by molecular imaging.

Autor: Zhang, Yun-Qi^1,2 (AUTHOR), Zhang, Wei^3,4 (AUTHOR), Kong, Xiang-Tai^3,4 (AUTHOR), Hai, Wang-Xi^1,2 (AUTHOR), Guo, Rui^1,2 (AUTHOR), Zhang, Min^1,2 (AUTHOR), Zhang, Su-Lin^3,4 (AUTHOR) slzhang@simm.ac.cn, Li, Biao^1,2 (AUTHOR) lb10363@rjh.com.cn

Publikováno v: Cancer Cell International. 5/29/2024, Vol. 24 Issue 1, p1-13. 13p.

Response Monitoring with [ ¹⁸ F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases.

Autor: Heskamp S; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. sandra.heskamp@radboudumc.nl., Heijmen L; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Gerrits D; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Molkenboer-Kuenen JDM; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Ter Voert EGW; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Heinzmann K; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Honess DJ; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Smith DM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Griffiths JR; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Doblas S; LBI, CRI - UMR 1149 Inserm, Université Paris Diderot, Paris, France., Sinkus R; BHF Centre of Excellence, Division of Imaging Sciences and Biomedical Engineering, King's College London, King's Health Partners, St. Thomas' Hospital, London, SE1 7EH, UK., Laverman P; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Oyen WJG; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Heerschap A; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Boerman OC; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Publikováno v: Molecular imaging and biology [Mol Imaging Biol] 2017 Aug; Vol. 19 (4), pp. 540-549.

The action of β-hydroxybutyrate on the growth, metabolism and global histone H3 acetylation of spontaneous mouse mammary tumours: evidence of a β-hydroxybutyrate paradox.

Autor: Rodrigues LM; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 ORE UK., Uribe-Lewis S; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 ORE UK., Madhu B; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 ORE UK., Honess DJ; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 ORE UK., Stubbs M; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 ORE UK., Griffiths JR; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 ORE UK.

Publikováno v: Cancer & metabolism [Cancer Metab] 2017 Feb 28; Vol. 5, pp. 4. Date of Electronic Publication: 2017 Feb 28 (Print Publication: 2017).

The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models.

Autor: Heinzmann K; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Present address: Comprehensive Cancer Imaging Centre, Imperial College London, London, UK., Honess DJ; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Lewis DY; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; CRUK-EPSRC Cancer Imaging Centre in Cambridge and Manchester, Cambridge, UK., Smith DM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Cawthorne C; Wolfson Molecular Imaging Centre, Manchester Pharmacy School, University of Manchester, Manchester, UK.; Present address: Positron Emission Tomography Research Centre, University of Hull, Hull, UK., Keen H; Personalised Healthcare and Biomarkers, AstraZeneca, Alderley Park, Macclesfield, UK., Heskamp S; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Schelhaas S; European Institute for Molecular Imaging (EIMI), Westfälische Wilhelms-Universität (WWU), University Hospital of Münster, Münster, Germany., Witney TH; Comprehensive Cancer Imaging Centre, Imperial College London, London, UK.; Present address: UCL Centre for Advanced Biomedical Imaging, University College London, London, UK., Soloviev D; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; CRUK-EPSRC Cancer Imaging Centre in Cambridge and Manchester, Cambridge, UK., Williams KJ; Wolfson Molecular Imaging Centre, Manchester Pharmacy School, University of Manchester, Manchester, UK.; CRUK-EPSRC Cancer Imaging Centre in Cambridge and Manchester, Cambridge, UK., Jacobs AH; European Institute for Molecular Imaging (EIMI), Westfälische Wilhelms-Universität (WWU), University Hospital of Münster, Münster, Germany., Aboagye EO; Comprehensive Cancer Imaging Centre, Imperial College London, London, UK., Griffiths JR; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Brindle KM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. kmb1001@cam.ac.uk.; CRUK-EPSRC Cancer Imaging Centre in Cambridge and Manchester, Cambridge, UK. kmb1001@cam.ac.uk.; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. kmb1001@cam.ac.uk.

Publikováno v: EJNMMI research [EJNMMI Res] 2016 Dec; Vol. 6 (1), pp. 63. Date of Electronic Publication: 2016 Aug 11.